$Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction$
Código QR

Código QR

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction

Guardado en:

Detalles Bibliográficos
Autores principales:	Ali Çoner, Ali Gökhan Özyıldız
Formato:	article
Lenguaje:	EN TR
Publicado:	KARE Publishing 2021
Materias:	Medicine R Internal medicine RC31-1245 Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/2c5ca921f4bc49848eb30cc5c8a1e85d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
por: Ali Çoner
Publicado: (2021)

Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy
por: Selda Murat, et al.
Publicado: (2021)

Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
por: Berkay Ekici, et al.
Publicado: (2021)

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
por: Mustafa Doğduş, et al.
Publicado: (2021)

Role of nutritional supplementation in heart failure with reduced ejection fraction
por: Yash Paul Sharma, et al.
Publicado: (2021)

Determinants of gait speed in patients with heart failure with reduced ejection fraction
por: Aylin Tanrıverdi, et al.
Publicado: (2021)

New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method
por: Ali Çoner
Publicado: (2021)

Depression in Heart Failure: Psychosomatic Approach
por: Rudi Putranto, et al.
Publicado: (2021)

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: M Rizzo, et al.
Publicado: (2020)

Management of Hyperkalemia in Heart Failure
por: Hakan Altay, et al.
Publicado: (2021)

Hyperkalemia in chronic heart failure
por: Hakan Altay
Publicado: (2021)

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction
por: M Rizzo, et al.
Publicado: (2020)

Classification of heart failure: A farewell to ejection fraction?
por: Thomas F. Lüscher
Publicado: (2021)

Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
por: Neal M Dixit, et al.
Publicado: (2021)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Mauro Gori, et al.
Publicado: (2021)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Veronika Zach, et al.
Publicado: (2020)

Evaluation of potential underuse of cardiac resynchronization therapy for heart failure with reduced ejection fraction
por: Makoto Takano, et al.
Publicado: (2021)

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Giuseppe MC Rosano, et al.
Publicado: (2019)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Davide Stolfo, et al.
Publicado: (2019)

Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction
por: Wan Ting Tay, et al.
Publicado: (2021)

Heart Failure 2019 Insights from the National Society of Cardiology journals
por: Plamen Gatzov, et al.
Publicado: (2021)

Cardiovascular disintegration: A conceptual, model-based approach to heart failure hemodynamics
por: Emre Aslanger, et al.
Publicado: (2021)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Hidekatsu Fukuta
Publicado: (2020)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Davide Margonato, et al.
Publicado: (2020)

Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study
por: Selda Murat, et al.
Publicado: (2021)

The Value of Serum Adiponectin in Osteoporotic Women: Does Weight Have an Effect?
por: Ali B. Roomi, et al.
Publicado: (2021)

Acute heart failure in pregnancy: importance of a timely multidisciplinary approach to recognition and management
por: Chacko Sanoj, et al.
Publicado: (2021)

A profile of heart failure with preserved ejection fraction in a teaching institute
por: Gaurav Aggarwal, et al.
Publicado: (2021)

Vagal Neuromodulation in Chronic Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis
por: Lucas Bonacossa Sant'Anna, et al.
Publicado: (2021)

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Sebastian Rosch, et al.
Publicado: (2020)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Sebastiaan HC Klaassen, et al.
Publicado: (2020)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021)

Curcumin and Mesenchymal Stem Cells Ameliorate Ankle, Testis, and Ovary Deleterious Histological Changes in Arthritic Rats via Suppression of Oxidative Stress and Inflammation
por: Rania H. Ahmed, et al.
Publicado: (2021)

Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure
por: Li-fang Ye, et al.
Publicado: (2021)

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction
por: Nicholas K Brownell, et al.
Publicado: (2021)

Heart bowtie
por: Maryam Shojaeifard, et al.
Publicado: (2021)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Mackram F Eleid, et al.
Publicado: (2021)

The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
por: Pankaj Jariwala, et al.
Publicado: (2021)

Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
por: Yibo He, et al.
Publicado: (2021)

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
por: Osama A. Amin, et al.
Publicado: (2021)